According to a dispatch from the Prensa Latina news agency, Cuba and China decided to speed up a project to establish the first joint biotech park to develop, produce and market the island’s drugs.
Cuban Ambassador to China Carlos Miguel Pereira and Huang Liansheng, president of Guangxi Fukang Medical Investment and Management Co. Ltd., said this is a key work of bilateral cooperation.
The biotech park is an agreement between the BioCubaFarma group and the aforementioned Chinese entity. It will be installed in the Fangchenggang Development Zone, with prospects of becoming an experimental industrial hub in drug research and procurement for China and the Association of Southeast Asian Nations.
It includes building a cooperative platform to provide better public health services and a joint venture that will develop Cuban drugs for heart and cerebrovascular disorders, and different cancers, among others.
According to Pereira, this work will open the way for other plans in a sector in which both countries have strong ties. He appreciated the efforts of Guangxi Fukang to promote the project and highlighted its relevance because it coincides with other initiatives by Cuba and the highest health, science and technology agencies in China in the perspective of developing products and therapies that can be linked to cooperation with third countries.
For his part, Liansheng said the project is among the main ones in the southern Guangxi Zhuang Autonomous Region. The local government promised preferential policies and has delivered 33 hectares of land for the first installations.
Initial products will include melangenin, heberferon, proctokinase, and therapeutic hepatitis B vaccine, all with proven results and wide-ranging prestige on the global market.
Authors
